GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Beaufort Securities in a research report issued on Friday. They currently have a GBX 1,750 ($21.87) price objective on the stock. Beaufort Securities’ price objective points to a potential upside of 10.76% from the company’s previous close.
Other research analysts have also recently issued research reports about the company. Jefferies Group LLC raised their target price on GlaxoSmithKline plc from GBX 1,900 ($23.74) to GBX 1,950 ($24.37) and gave the company a “buy” rating in a research note on Thursday, October 13th. Bryan, Garnier & Co reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, October 17th. Sanford C. Bernstein set a GBX 1,834 ($22.92) target price on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, October 19th. J P Morgan Chase & Co reaffirmed a “neutral” rating and set a GBX 1,667 ($20.83) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, October 19th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 1,800 ($22.49) target price on GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Wednesday, October 19th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of GBX 1,744.55 ($21.80).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1570.00 on Friday. GlaxoSmithKline plc has a 12 month low of GBX 1,342.50 and a 12 month high of GBX 1,745.56. The firm’s market cap is GBX 76.43 billion. The stock’s 50 day moving average is GBX 1,556.68 and its 200 day moving average is GBX 1,598.00.
The business also recently disclosed a dividend, which will be paid on Thursday, April 13th. Stockholders of record on Thursday, February 23rd will be issued a dividend of GBX 23 ($0.29) per share. This is a positive change from GlaxoSmithKline plc’s previous dividend of $19.00. The ex-dividend date of this dividend is Thursday, February 23rd. This represents a dividend yield of 1.47%.
This article was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The legal version of this article can be read at http://sleekmoney.com/glaxosmithkline-plc-gsk-stock-rating-reaffirmed-by-beaufort-securities/1659430.html.
In other news, insider Victoria Whyte sold 4,820 shares of the stock in a transaction dated Thursday, February 9th. The stock was sold at an average price of GBX 1,576 ($19.70), for a total transaction of £75,963.20 ($94,930.27). Also, insider Vivienne Cox acquired 342 shares of the stock in a transaction dated Wednesday, February 8th. The shares were bought at an average cost of GBX 1,555 ($19.43) per share, for a total transaction of £5,318.10 ($6,645.96). In the last three months, insiders have bought 416 shares of company stock worth $670,778.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/glaxosmithkline-plc-gsk-stock-rating-reaffirmed-by-beaufort-securities/1659430.html
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.